Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CLPP | Q16740 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28372237 | 0.88 | VCAM1 (0.49) | ITGB1ITGA5ALDH1A1HIF1AKMT2A | |
| SCHEMBL29221076 | 0.87 | ATM (0.51) | ITGB1ITGA5ALDH1A1LMNAKMT2A | |
| SCHEMBL12061581 | 0.85 | ALDH1A1 (0.51) | ITGB1ITGA5ALDH1A1HIF1ALMNA | |
| SCHEMBL8191291 | 0.85 | ALDH1A1 (0.51) | ITGB1ITGA5ALDH1A1HIF1ALMNA | |
| SCHEMBL16132076 | 0.84 | GSK3B (0.56) | ITGB1ITGA5ALDH1A1HIF1ALMNA | |
| SCHEMBL177107 | 0.84 | ALDH1A1 (0.50) | ITGB1ITGA5ALDH1A1HIF1ALMNA | |
| SCHEMBL28371978 | 0.83 | SMN1; SMN2 (0.51) | ITGB1ITGA5ALDH1A1HIF1ALMNA | |
| SCHEMBL21775014 | 0.82 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL7047805 | 0.82 | TSHR (0.68) | ALDH1A1LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL9157 | 0.81 | ITGB1 (0.57) | ITGB1ITGA5ALDH1A1HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| CN-110803992-B | Preparation method of 3-nitro-4-fluoroacetophenone acetate | 暨明医药科技（苏州）有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102712577-A | Substituted 3-phenylpropionic acids and the use thereof | BAYER SCHERING PHARMA AG | 2012-10-03 | — | — | CN | disclosed |
| CN-102361859-A | Heteroaryl compounds useful as Raf kinase inhibitors | BIOGEN IDEC INC | 2012-02-22 | — | — | CN | disclosed |
| CN-102171191-A | Indazole derivative | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110190400-A1 | Novel Compounds for Treatment of Malignant Tumors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-04 | — | — | US | disclosed |
| CN-1265651-A | Novel tricyclic compound having saturated ring and pharmaceutical composition thereof | ASAHI CHEMICAL IND (JP) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | ITGB1 4747/4885ITGA5 4386/4885ALDH1A1 1872/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | ITGB1 4747/4885ITGA5 4386/4885ALDH1A1 1872/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | ITGB1 4747/4885ITGA5 4386/4885ALDH1A1 1872/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | ITGB1 4056/4885ITGA5 3935/4885ALDH1A1 1757/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | ITGB1 4811/4885ITGA5 4461/4885ALDH1A1 1697/4885 |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | ITGB1 2493/4885ITGA5 2304/4885ALDH1A1 2598/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | ITGB1 4747/4885ITGA5 4386/4885ALDH1A1 1872/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | ITGB1 4184/4885ITGA5 4125/4885ALDH1A1 491/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | ITGB1 4184/4885ITGA5 4125/4885ALDH1A1 491/4885 |
| US-20110190400-A1 | Novel Compounds for Treatment of Malignant Tumors | TP53, CHEK1, CHEK2 | ITGB1 2630/4885ITGA5 2771/4885ALDH1A1 1483/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | ITGB1 4773/4885ITGA5 4628/4885ALDH1A1 1046/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | ITGB1 4747/4885ITGA5 4386/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.